INS and metabolic dysfunction-associated steatohepatitis: Early reports indicate that UDCA improves glucose metabolism; that is, administration of high-dose UDCA improves glycemic parameters, insulin sensitivity, and insulin resistance surrogate markers in patients with NASH [12,13].